Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16449534 | 0.77 | GAA (0.36) | GAAMAPT | |
| SCHEMBL4283708 | 0.74 | GAA (0.44) | GAAMAPTP2RX4 | |
| SCHEMBL15356598 | 0.71 | TRPA1 (0.38) | GAAMAPT | |
| SCHEMBL16293542 | 0.70 | GAA (0.38) | GAAMAPTP2RX4 | |
| SCHEMBL16293682 | 0.70 | GAA (0.38) | GAAMAPTP2RX4 | |
| SCHEMBL6111309 | 0.69 | GAA (0.44) | GAAMAPTP2RX4 | |
| SCHEMBL4540870 | 0.69 | GAA (0.44) | GAAMAPT | |
| SCHEMBL18562457 | 0.69 | GAA (0.44) | GAAMAPT | |
| SCHEMBL12159337 | 0.69 | GAA (0.44) | GAAMAPTP2RX4 | |
| SCHEMBL6056252 | 0.69 | GAA (0.44) | GAAMAPTP2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2023-01-05 | — | — | US | claimed |
| CN-106660998-B | Pyrazolyl-3, 4-dihydroquinolin-2-one aldosterone synthase inhibitors | 豪夫迈·罗氏有限公司 | 2019-10-25 | — | — | CN | claimed |
| WO-2017165489-A1 | ANTIVIRAL AGENTS FOR TREATING ZIKA AND DENGUE VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2017-09-28 | — | — | WO | claimed |
| CN-106660998-A | Pyrazolyl-3, 4-dihydroquinolin-2-one aldosterone synthase inhibitors | 豪夫迈·罗氏有限公司 | 2017-05-10 | — | — | CN | claimed |
| CN-106604917-A | Novel dihydroquinoline pyrazolyl compounds as aldosterone synthase inhibitors | 豪夫迈·罗氏有限公司 | 2017-04-26 | — | — | CN | claimed |
| CN-104744476-B | IMIDAZOPYRAZINE Syk INHIBITORS | 吉利德康涅狄格公司 | 2017-04-12 | — | — | CN | claimed |
| EP-2694086-A1 | MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE | The Texas A&M University System (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012138708-A1 | MHC ENGAGEMENT AND CLIP MODULATION FOR THE TREATMENT OF DISEASE | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-10-11 | — | — | WO | claimed |
| WO-2012135632-A2 | METHODS OF TREATING A SUBJECT HAVING BEEN EXPOSED TO A CATASTROPHIC EVENT | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-10-04 | — | — | WO | claimed |
| EP-1261340-A4 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RES GROUP LLC (US) | 2005-05-04 | — | — | EP | claimed |
| JP-2004500331-A | — | — | 2004-01-08 | — | — | JP | claimed |
| EP-1261340-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | Alpha Research Group, LLC (US) | 2002-12-04 | — | — | EP | claimed |
| WO-2001003649-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE | ALPHA RESEARCH GROUP, LLC (US) | 2001-01-18 | — | — | WO | claimed |
| US-4046765-A | Dihydroquinoline derivatives of antioxidant activity and a process for the preparation thereof | MATERIAL KSZ. (HU) | 1977-09-06 | — | — | US | claimed |
| US-20240216414-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2024-07-04 | — | — | US | disclosed |
| US-11963972-B2 | Antiviral agents and nucleoside analogs for treatment of Zika virus | EMORY UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2023208172-A1 | SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BEIGENE , LTD. (KY) | 2023-11-02 | — | — | WO | disclosed |
| CN-1121715-A | 4-aryl-4-hydroxy-tetrahydropyrans and 3-aryl-3-hydroxy-tetrahydrofurans as 5-lipoxygenase inhibitors | ZENECA LTD (GB) | 1996-05-01 | — | — | CN | disclosed |
| CN-1031266-C | Process for preparation of heterocycle ether derivatives | ZENECA LTD (GB) | 1996-03-13 | — | — | CN | disclosed |
| CN-1046903-A | Process for preparing heterocyclic ether derivatives | ICI PLC (GB) | 1990-11-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | GAA 1906/4885MAPT 3678/4885P2RX4 39/4885 |
| US-11963972-B2 | Antiviral agents and nucleoside analogs for treatment of Zika virus | SAMHD1, PNP, NUDT1 | GAA 1906/4885MAPT 3678/4885P2RX4 39/4885 |
| US-20240216414-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | GAA 1906/4885MAPT 3678/4885P2RX4 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.